We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00696423
First Posted: June 12, 2008
Last Update Posted: December 8, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
Results First Submitted: July 17, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Prevention
Conditions: Acellular Pertussis
Diphtheria
Tetanus
Interventions: Biological: Infanrix™
Biological: Hiberix™

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Infanrix/Hib Single Injection Group Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
Infanrix + Hiberix Separate Injection Group Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.

Participant Flow:   Overall Study
    Infanrix/Hib Single Injection Group   Infanrix + Hiberix Separate Injection Group
STARTED   244   223 
COMPLETED   244   218 
NOT COMPLETED   0   5 
Lost to Follow-up                0                5 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Infanrix/Hib Single Injection Group Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
Infanrix + Hiberix Separate Injection Group Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
Total Total of all reporting groups

Baseline Measures
   Infanrix/Hib Single Injection Group   Infanrix + Hiberix Separate Injection Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 244   223   467 
Age 
[Units: Months]
Mean (Standard Deviation)
 19.2  (0.79)   19.2  (0.75)   19.2  (0.77) 
Gender 
[Units: Participants]
Count of Participants
     
Female      113  46.3%      111  49.8%      224  48.0% 
Male      131  53.7%      112  50.2%      243  52.0% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations   [ Time Frame: One month after booster vaccination ]

2.  Primary:   Anti-diphtheria Toxoid Antibody Concentrations   [ Time Frame: One month after booster vaccination ]

3.  Primary:   Anti-tetanus Toxoid Antibody Concentrations   [ Time Frame: One month after booster vaccination ]

4.  Primary:   Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations   [ Time Frame: One month after booster vaccination ]

5.  Primary:   The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies   [ Time Frame: One month after booster vaccination ]

6.  Secondary:   Anti-PRP Antibody Concentrations   [ Time Frame: Before booster vaccination ]

7.  Secondary:   Anti-diphtheria Toxoid Antibody Concentrations   [ Time Frame: Before booster vaccination ]

8.  Secondary:   Anti-tetanus Toxoid Antibody Concentrations   [ Time Frame: Before booster vaccination ]

9.  Secondary:   Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations   [ Time Frame: Before booster vaccination ]

10.  Secondary:   The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies   [ Time Frame: Before booster vaccination ]

11.  Secondary:   Number of Subjects Reporting Solicited Local and General Symptoms   [ Time Frame: During the 4-day follow-up period after booster vaccination ]

12.  Secondary:   Number of Subjects Reporting Unsolicited Adverse Events (AE)   [ Time Frame: During the 31-day follow-up period after booster vaccination ]

13.  Secondary:   Number of Subjects Reporting Serious Adverse Events (SAE)   [ Time Frame: During the 31-day follow-up period after booster vaccination ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343



Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00696423     History of Changes
Other Study ID Numbers: 111535
First Submitted: June 5, 2008
First Posted: June 12, 2008
Results First Submitted: July 17, 2009
Results First Posted: August 26, 2009
Last Update Posted: December 8, 2016